Senate CHIPS Bender
CHIPS+ is corporate welfare. Congress may call it a grant, but
the trade term in this context is a subsidy. The bill does not seem to
directly discriminate against foreign semiconductor manufacturers, but it
does provide an incentive that foreign producers could see as unfair. The
United States has countervailing duty laws in place to address subsidies like
this one provided by foreign governments. These duties (also known as
tariffs) make the imports more expensive in the U.S. market. Other countries
have similar laws, and it is likely that U.S. semiconductor exports could be
subject to such duties as a consequence of CHIPS+.
A CHIPS bill, with a starting price tag of $16 billion,
was originally proposed to address the COVID-19 pandemic-related
semiconductor shortage. In 2020, when this first proposal came about,
semiconductor producers were more concerned with running their businesses
than with lobbying Congress for subsidies. A new piece
by AAF’s Fred Ashton details the private-sector investment currently planned
to expand domestic and global semiconductor production: nearly $80 billion in
new U.S. investment by 2025 and more than $800 billion in spending globally
over the next 10 years. CHIPS+ is an unnecessary and wasteful handout to
solve a shortage that the private sector is already addressing. |
To be a Medicare Agent's source of information on topics affecting the agent and their business, and most importantly, their clientele, is the intention of this site. Sourced from various means rooted in the health insurance industry - insurance carriers, governmental agencies, and industry news agencies, this is aimed as a resource of varying viewpoints to spark critical thought and discussion. We welcome your contributions.
Tuesday, August 2, 2022
Senate CHIPS Bender
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment